INFLARX ($IFRX) posted quarterly earnings results on Wednesday, May 7th. The company reported earnings of -$0.12 per share, beating estimates of -$0.19 by $0.06. The company also reported revenue of $0, missing estimates of $198,390 by $-198,390.
You can see Quiver Quantitative's $IFRX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
INFLARX Hedge Fund Activity
We have seen 14 institutional investors add shares of INFLARX stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 1,370,035 shares (+205.1%) to their portfolio in Q4 2024, for an estimated $3,383,986
- EVERSEPT PARTNERS, LP removed 1,129,335 shares (-69.6%) from their portfolio in Q4 2024, for an estimated $2,789,457
- IKARIAN CAPITAL, LLC removed 704,987 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,741,317
- NORTHERN TRUST CORP added 634,045 shares (+1933.1%) to their portfolio in Q4 2024, for an estimated $1,566,091
- OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) removed 172,287 shares (-21.6%) from their portfolio in Q4 2024, for an estimated $425,548
- UBS GROUP AG added 67,441 shares (+inf%) to their portfolio in Q4 2024, for an estimated $166,579
- CITADEL ADVISORS LLC added 27,973 shares (+121.9%) to their portfolio in Q4 2024, for an estimated $69,093
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
INFLARX Analyst Ratings
Wall Street analysts have issued reports on $IFRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Guggenheim issued a "Buy" rating on 03/26/2025
To track analyst ratings and price targets for INFLARX, check out Quiver Quantitative's $IFRX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.